IGC Pharma Inc IGC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IGC is a good fit for your portfolio.
News
-
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
-
IGC Pharma Adds Advisor in Artificial Intelligence
-
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
-
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
-
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
-
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
-
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
-
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
Trading Information
- Previous Close Price
- $0.44
- Day Range
- $0.46–0.65
- 52-Week Range
- $0.26–0.90
- Bid/Ask
- $0.51 / $0.53
- Market Cap
- $34.93 Mil
- Volume/Avg
- 4.2 Mil / 816,989
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 26.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 61
- Website
- https://www.igcinc.us
Valuation
|
Metric
|
IGC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.05 |
Price/Sales | 26.50 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IGC
|
|---|---|
Quick Ratio | 0.77 |
Current Ratio | 1.85 |
Interest Coverage | — |
Quick Ratio
IGC
Profitability
|
Metric
|
IGC
|
|---|---|
Return on Assets (Normalized) | −38.10% |
Return on Equity (Normalized) | −44.18% |
Return on Invested Capital (Normalized) | −42.81% |
Return on Assets
IGC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lczxfdpjmr | Gtxmp | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gyqhfjcz | Vbdqcq | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lkxfstbm | Jvvyckf | $98.6 Bil | |
MRNA
| Moderna Inc | Hrxvjtby | Xbcw | $41.0 Bil | |
ARGX
| argenx SE ADR | Qlhfvpyky | Kllz | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Zvssnsdn | Fnjj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cqvyfzgk | Kqcpcs | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pkybtxzn | Ybhxnb | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vtyllkkbm | Vtltx | $12.6 Bil | |
INCY
| Incyte Corp | Wgldtwchj | Vxczj | $12.0 Bil |